February 15, 2022 News by Steve Bryson, PhD VISIONARY-MS Trial of CNM-Au8 to End Early Due to Pandemic VISIONARY-MS, a Phase 2 clinical trial evaluating the safety and effectiveness of CNM-Au8 in people with relapsing multiple sclerosis (MS) with disease-related visual impairment, will conclude early due to COVID-19 pandemic-related challenges. The release of trial data is expected in the second half of this year, according to…
August 6, 2021 News by Steve Bryson, PhD CNM-Au8 Seen to Raise Energy Metabolism of Brain in RRMS Trial Cleneās investigational oral therapy CNM-Au8 improved energy metabolism in the brain of adults with relapsing-remitting multiple sclerosis (RRMS), according to top-line results from the REPAIR-MS trial. This open-label Phase 2 pilot study (NCT03993171), taking place in Texas, is running in parallel with REPAIR-PD, another Phase 2…
January 20, 2021 News by Marisa Wexler, MS Clene Awaits US Patent Covering Gold Nanocrystals’ Use in Treating MS Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent…
March 16, 2020 News by Ana Pena PhD #ACTRIMS2020 – CNM-Au8 a Potential ‘Breakthrough’ in MS Therapy, Clene CMO Says An investigational therapy that uses nanocrystals of gold to help the brain repair itself represents a breakthrough in the multiple sclerosis (MS) field, says Clene Nanomedicine‘s chief medical officer Robert Glanzman. Glanzman, MD, recently presented promising results at the ACTRIMS Forum 2020 indicating that Clene’s lead…
January 13, 2020 News by Marisa Wexler, MS First MS Patient Dosed in Phase 2 Trial of Potential Remyelinating Therapy CNM-Au8, Clene Announces The first participant has been dosed in the Phase 2 REPAIR-MS clinical trial examining the effects of CNM-Au8,Ā Clene Nanomedicine‘s investigational remyelinating therapy, on brain metabolism in people with multiple sclerosis (MS), the company announced. In MS, the immune system attacks myelin, the protective sheath that surrounds…
October 16, 2019 News by Alice MelĆ£o, MSc NMSS Awards $339K to Phase 2 Trial of Potential Remyelination Agent, Clene Nanomedicine Announces The National Multiple Sclerosis Society awarded more than $339,000 to Clene Nanomedicine to support clinical tests into its lead candidate CNM-Au8Ā in treatingĀ multiple sclerosis (MS) by protecting nerve cells and restoring myelin. The grant was awarded under the National MS Societyās Fast Forward program, which aims…